FindTrial
Sign In

A medical records based study for predictive value of plasma high-sensitivity C-reactive protein/albumin for death in patients with acute coronary syndrome

Predictive value of plasma high-sensitivity C-reactive protein/albumin for death in patients with acute coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044143
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

The patients were divided into 3 groups: Acute ST-segment Elevation Myocardial Infarction, acute non-ST-segment elevation myocardial infarction and unstable Angina pectoris:Nil

Sponsors

Beijing Anzhen Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
56 Years to 78 Years

Inclusion criteria

Inclusion criteria: According to the 2018 JCS guideline: The definition of ACS in the diagnosis and treatment of Acute Coronary Syndrome [7] ; one or more coronary stenosis >= 50% was confirmed by coronary angiography.

Exclusion criteria

Exclusion criteria: Myocarditis, cardiomyopathy; acute and chronic heart failure, ejection fraction < 45%; combined liver, kidney, lung disease, acute brain injury, acute pancreatitis; Blood Diseases, tumors.

Design outcomes

Primary

MeasureTime frame
plasma high-sensitivity C-reactive protein/albumin;BNP;—

Countries

China

Contacts

Public ContactZhang Ning

Beijing Anzhen Hospital

ringchang@126.com+86 13522960438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026